A networked swellable dextrin nanogels loading Bcl2 siRNA for melanoma tumor therapy

被引:0
|
作者
Huipeng Li
Zhanwei Zhou
Feiran Zhang
Yuxin Guo
Xue Yang
Hulin Jiang
Fei Tan
David Oupicky
Minjie Sun
机构
[1] China Pharmaceutical University,State Key Laboratory of Natural Medicines and Department of Pharmaceutics
[2] University of Nebraska Medical Center,Center for Drug Delivery and Nanomedicine, Department of Pharmaceutical Sciences
[3] Skin Disease Hospital of Tongji University,Shanghai Skin Disease Hospital
来源
Nano Research | 2018年 / 11卷
关键词
dextrin nanogels; local enrichment; reduction-responsive; lysosomal escape; disulfide cross-linked; small interfering RNA (siRNA) delivery;
D O I
暂无
中图分类号
学科分类号
摘要
In this study, a networked swellable dextrin nanogel (DNG) was developed to achieve stimulated responsive small interfering RNA (siRNA) release for melanoma tumor therapy. siRNA was loaded into multidimensional dextrin nanogels by charge condensation with positive arginine residues modified in the dextrin backbone. Moreover, the networked nanogel was destroyed and loosened based on its bioreducible responsive property to control accelerated siRNA release in a bioreducible intracellular environment, while it remained stable under normal physiological conditions. We demonstrated that DNGs had swellable and disassembly properties under reduced buffer condition by transmission electron microscopy evaluation. The DNGs achieved an endosomal escape followed by selective release of the cargo into the cytosol by glutathione-triggered disassembly according to confocal microscopy observation. Thus, this smart nanogel achieved outstanding luciferase gene silencing efficiency and decreased Bcl2 protein expression in vitro and in vivo based on western blot analysis. Moreover, this nanogel exhibited superior anti-tumor activity for B16F10 xenograft tumors in C57BL/6 mice. These results demonstrate that the networked DNGs are effective for gene condensation and controlled intracellular release for tumor therapy. Overall, these findings suggest that this multidimensional swellable stimuli-responsive dextrin nanogel is an innovative strategy with great promise for gene and drug delivery.
引用
收藏
页码:4627 / 4642
页数:15
相关论文
共 50 条
  • [41] Small-Molecule Bcl2 BH4 Antagonist for Lung Cancer Therapy
    Han, Bingshe
    Park, Dongkyoo
    Li, Rui
    Xie, Maohua
    Owonikoko, Taofeek K.
    Zhang, Guojing
    Sica, Gabriel L.
    Ding, Chunyong
    Zhou, Jia
    Magis, Andrew T.
    Chen, Zhuo G.
    Shin, Dong M.
    Ramalingam, Suresh S.
    Khuri, Fadlo R.
    Curran, Walter J.
    Deng, Xingming
    CANCER CELL, 2015, 27 (06) : 852 - 863
  • [42] INHIBITION OF BCL2 IS AN EFFECTIVE NEW APPROACH TO THERAPY FOR B-CELL LYMPHOPROLIFERATIVE DISEASES
    Roberts, A. W.
    Anderson, M. A.
    Khaw, S. L.
    Huang, D.
    CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2013, 40 : 11 - 11
  • [43] Optimizing BH3 mimetic therapy: Insights from BCL2 inhibition in the clinic
    Roberts, Andrew
    CANCER RESEARCH, 2016, 76
  • [44] Interference Of The Tumor Supportive Effects Of BCL2 and MCL1 Sensitize Malignant Plasma Cells To The Lethal Effects Of Lenalidomide and Dexamethasone Regimen: An Important Clinical Path For BCL2 Targeting Drugs
    Paulus, Aneel
    Chitta, Kasyapa S.
    Akhtar, Sharoon
    Kuranz, Maja
    Kumar, Shaji
    Roy, Vivek
    Ansell, Stephen M.
    Mikhael, Joseph R.
    Dispenzieri, Angela
    Reeder, Craig
    Rivera, Candido E.
    Foran, James M.
    Buadi, Francis
    Rajkumar, Vincent
    Chanan-Khan, Asher
    BLOOD, 2013, 122 (21)
  • [45] TUMOR-CELL KILLING BY Y-90 LABELED BCL2 ANTISENSE OLIGODEOXYNUCLEOTIDE PROBES
    DEWANJEE, MK
    GHAFOURIPOUR, AK
    HANNA, M
    SUBRAMANIAN, M
    WILLEM, L
    KAPADVANJWALA, M
    LOPEZ, DM
    SERAFINI, AN
    SFAKIANAKIS, N
    PROTEIN ENGINEERING, 1995, 8 : 84 - 84
  • [46] Overexpression of the BCL2 gene in a Sertoli-Leydig cell tumor of the ovary:: a pathologic and cytogenetic study
    Truss, L
    Dobin, SA
    Rao, A
    Donner, LR
    CANCER GENETICS AND CYTOGENETICS, 2004, 148 (02) : 118 - 122
  • [47] Systemic delivery of siRNA specific to tumor mediated by atelocollagen: Combined therapy using siRNA targeting Bcl-xL and cisplatin against prostate cancer
    Mu, Ping
    Nagahara, Shunji
    Makita, Naoki
    Tarumi, Yuzo
    Kadomatsu, Kenji
    Takei, Yoshifumi
    INTERNATIONAL JOURNAL OF CANCER, 2009, 125 (12) : 2978 - 2990
  • [48] Combination silencer RNA (siRNA) targeting Bcl-2 antagonizes siRNA against thymidylate synthase in human tumor cell lines
    Pandyra, Aleksandra A.
    Berg, Randal
    Vincent, Mark
    Koropatnick, James
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2007, 322 (01): : 123 - 132
  • [49] Tumor characteristics, expressions of ERCC1, Bax, p53, IGF1R, Bcl2, Bcl2/Bax and prognostic factors for overall survival in patients with lung carcinoid
    Velinovic, Marta
    Jankovic, Radmila
    Jovanovic, Dragana
    Trifunovic, Vesna Skodric
    Gavrilovic, Dusica
    Stojsic, Jelena
    Cavic, Milena
    JOURNAL OF BUON, 2019, 24 (01): : 256 - 266
  • [50] Targeted Delivery of BCL-2 siRNA Using Modified Ferritin Nanocarriers for Antitumor Therapy
    Qin, Li-Miao
    Feng, Meng-Fan
    Sun, Bo
    Yu, Xianghui
    Wu, Yuqing
    ACS APPLIED NANO MATERIALS, 2024, 7 (19) : 22487 - 22496